Comparison
Survodutide vs. TB-500
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Healing
CAS no.
2179963-22-7
no data
Molecular weight
4727 g/mol
888 g/mol
Half-life
168 h
no data
Sequence
modifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteAc-LKKTETQMechanism of action
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
TB-500
Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.
Evidence base
Highest evidence
Human RCT
Animal model
Studies
2
3
of which in humans
2
0
Effects recorded
3
4
Open conflicts
0
1
Documented adverse events
2
2